Sangamo Therapeutics, Inc. (SGMO) Sr. VP & Chief Medical Officer Edward Conner, Sold $92,436 in Stock; Greenhill & Co (GHL) Sentiment Is 1.21

The Sr. VP & Chief Medical Officer of Sangamo Therapeutics Inc, Edward Conner recently got nearly $92,436 US Dollars for 5,000 shares in the Sangamo Therapeutics Inc firm at an around $18.5 for every share. This is not his first insider trade, in the last 30 days, he sold another 5,000 shares worth $85,545 USD. Currently, Edward Conner owns 8,125 shares or 0.01% of Sangamo Therapeutics Inc’s market capitalization. The document was revealed in a filing dated February 7, 2018 with the SEC.

Greenhill & Co., Inc., together with its subsidiaries, operates as an independent investment bank for firms, partnerships, institutions, and governments worldwide. The company has market cap of $497.95 million. The firm provides financial advisory services primarily related to mergers and acquisitions, restructurings, financings, and capital raisings. It has a 25.66 P/E ratio. It is involved in the provision of advisory services to clients in relation to domestic and cross-border mergers, acquisitions, divestitures, spin-offs, and other strategic transactions, as well as various stages of these transactions, from initial structuring to final execution.

Ratings analysis reveals 0 of Greenhill’s analysts are positive. Out of 3 Wall Street analysts rating Greenhill, 0 give it “Buy”, 3 “Sell” rating, while 0 recommend “Hold”. GHL was included in 3 notes of analysts from December 14, 2016. The firm has “Reduce” rating by Nomura given on Thursday, January 5. Goldman Sachs downgraded the shares of GHL in report on Tuesday, January 10 to “Sell” rating. Bank of America initiated the shares of GHL in report on Wednesday, December 14 with “Underperform” rating.

Rutabaga Capital Management Llc Ma holds 4.23% of its portfolio in Greenhill & Co., Inc. for 1.19 million shares. Capital Management Corp Va owns 676,661 shares or 3.21% of their US portfolio. Moreover, Adirondack Research & Management Inc. has 2% invested in the company for 308,336 shares. The Florida-based Intrepid Capital Management Inc has invested 1.19% in the stock. Skyline Asset Management Lp, a Illinois-based fund reported 844,100 shares.

The stock increased 9.52% or $1.6 during the last trading session, reaching $18.4. About 1.54M shares traded or 179.95% up from the average. Greenhill & Co., Inc. (GHL) has risen 14.04% since February 8, 2017 and is uptrending. It has underperformed by 2.66% the S&P500.

The stock increased 12.98% or $2.55 during the last trading session, reaching $22.2. About 3.47M shares traded or 129.58% up from the average. Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has risen 29.78% since February 8, 2017 and is uptrending. It has outperformed by 13.08% the S&P500.

Among 10 analysts covering Sangamo Biosciences (NASDAQ:SGMO), 7 have Buy rating, 1 Sell and 2 Hold. Therefore 70% are positive. Sangamo Biosciences has $25.0 highest and $4 lowest target. $18.20’s average target is -18.02% below currents $22.2 stock price. Sangamo Biosciences had 22 analyst reports since August 8, 2015 according to SRatingsIntel. The stock has “Sell” rating by Zacks on Tuesday, September 8. The stock of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has “Overweight” rating given on Wednesday, November 15 by PiperJaffray. The stock of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) earned “Buy” rating by Wedbush on Wednesday, September 2. The company was maintained on Monday, August 14 by Wedbush. The firm earned “Neutral” rating on Wednesday, October 19 by PiperJaffray. The firm has “Buy” rating by Jefferies given on Tuesday, September 12. As per Wednesday, October 19, the company rating was downgraded by Piper Jaffray. On Saturday, August 8 the stock rating was maintained by JP Morgan with “Overweight”. The rating was reinitiated by Jefferies with “Buy” on Thursday, June 22. The stock of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) earned “Buy” rating by JP Morgan on Thursday, September 3.

Investors sentiment decreased to 1.57 in Q3 2017. Its down 0.02, from 1.59 in 2017Q2. It dropped, as 17 investors sold Sangamo Therapeutics, Inc. shares while 32 reduced holdings. 27 funds opened positions while 50 raised stakes. 51.93 million shares or 2.16% more from 50.83 million shares in 2017Q2 were reported. Moreover, Principal Financial Group Inc has 0% invested in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Advisory Lc accumulated 300 shares. Manufacturers Life Ins The holds 0% or 62,973 shares. Susquehanna Group Llp holds 0% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) or 346,533 shares. 213,027 are held by Eam Lc. Northern Tru Corporation holds 0% or 1.07M shares. Prelude Cap Mngmt Ltd Liability Corporation reported 1,350 shares stake. Tower Research Cap (Trc) stated it has 2,551 shares or 0% of all its holdings. Federated Invsts Inc Pa has 0.01% invested in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) for 176,794 shares. Adage Cap Grp Ltd Liability Company holds 0.12% or 3.20 million shares in its portfolio. Bain Capital Public Equity Mgmt Limited Liability Com holds 0.19% of its portfolio in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) for 203,791 shares. Switzerland-based Zurcher Kantonalbank (Zurich Cantonalbank) has invested 0% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). State Board Of Administration Of Florida Retirement System invested in 61,070 shares. Millennium Ltd Co holds 0.02% or 942,097 shares. Neuberger Berman Group Lc holds 0% or 21,000 shares.

Since August 11, 2017, it had 0 insider purchases, and 7 sales for $1.79 million activity. Herberts Curt A. III sold $119,740 worth of stock. $85,545 worth of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) was sold by Conner Edward R. $445,597 worth of stock was sold by RINGO WILLIAM R on Wednesday, September 20. Shares for $237,159 were sold by Mento Steven J.

Sangamo Therapeutics, Inc. focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company has market cap of $1.88 billion. The company??s zinc finger DNA-binding protein technology enables specific genome editing and gene regulation. It currently has negative earnings. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to specifically modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off.

Analysts await Sangamo Therapeutics, Inc. (NASDAQ:SGMO) to report earnings on February, 27. They expect $-0.18 EPS, down 28.57% or $0.04 from last year’s $-0.14 per share. After $-0.15 actual EPS reported by Sangamo Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 20.00% negative EPS growth.